AEHR vs. TXG, EYPT, ALNT, TRNS, LAB, CTKB, SENS, QSI, FEIM, and MASS
Should you be buying Aehr Test Systems stock or one of its competitors? The main competitors of Aehr Test Systems include 10x Genomics (TXG), EYEPOINT PHARMACEUTICALS (EYPT), Allient (ALNT), Transcat (TRNS), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Aehr Test Systems vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Aehr Test Systems (NASDAQ:AEHR) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 6.8% of Aehr Test Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, 10x Genomics and 10x Genomics both had 9 articles in the media. 10x Genomics' average media sentiment score of 0.77 beat Aehr Test Systems' score of 0.15 indicating that 10x Genomics is being referred to more favorably in the media.
Aehr Test Systems has lower revenue, but higher earnings than 10x Genomics. Aehr Test Systems is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
10x Genomics presently has a consensus target price of $13.65, indicating a potential upside of 4.87%. Given 10x Genomics' stronger consensus rating and higher possible upside, equities analysts clearly believe 10x Genomics is more favorable than Aehr Test Systems.
10x Genomics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Aehr Test Systems has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500.
Aehr Test Systems has a net margin of -6.63% compared to 10x Genomics' net margin of -13.13%. Aehr Test Systems' return on equity of -0.15% beat 10x Genomics' return on equity.
Summary
10x Genomics beats Aehr Test Systems on 8 of the 15 factors compared between the two stocks.
Get Aehr Test Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aehr Test Systems Competitors List
Related Companies and Tools
This page (NASDAQ:AEHR) was last updated on 10/6/2025 by MarketBeat.com Staff
